诺如病毒疫苗在社区接种的临床与经济价值阈值
该研究基于美国不同人群的诺如病毒传播、临床与经济计算模拟模型,评估接种5岁以下儿童和65岁及以上老年人的效果与成本阈值。结果显示接种儿童可避免8%-72%有症状病例,老年人避免2%-29%,并给出了不同疫苗效力下的成本效益与成本节约阈值。
要点
- 接种5岁以下儿童可避免8%-72%有症状诺如病毒病例。
- 接种65岁及以上老年人可避免2%-29%有症状病例。
- 疫苗效力25%-75%与覆盖率10%-80%影响成本效益阈值。
核心结论
- 研究明确了在社区接种5岁以下儿童和65岁及以上老年人时,诺如病毒疫苗具有成本效益和成本节约的阈值。
研究设计与样本
- 2020年开发了代表美国不同人群的诺如病毒传播、临床与经济计算模拟模型。
主要发现
- 与不接种相比,接种5岁以下儿童避免8%-72%有症状病例,接种老年人避免2%-29%,随疫苗效力25%-75%和覆盖率10%-80%变化。
关键数值与推荐
- 疫苗效力25%时,接种5岁以下儿童成本效益阈值≤445美元、成本节约阈值≤370美元;接种老年人分别为≤42美元和≤30美元。
- 疫苗效力50%时,接种5岁以下儿童成本效益阈值≤1190美元、成本节约阈值≤930美元;接种老年人分别为≤110美元和≤64美元。
- 疫苗效力75%时,接种5岁以下儿童成本效益阈值≤1600美元、成本节约阈值≤1300美元;接种老年人分别为≤165美元和≤100美元。
临床怎么用
- 决策者可参考这些成本阈值,在开发和实施诺如病毒疫苗时设定目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: With norovirus vaccine candidates currently under development, now is the time to identify the vaccine characteristics and implementation thresholds at which vaccination becomes cost effective and cost saving in a community setting. METHODS: In 2020, a norovirus transmission, clinical, and economics computational simulation model representing different U.S. population segments was developed to simulate the spread of norovirus and the potential impact of vaccinating children aged <5 years and older adults (aged ≥65 years). RESULTS: Compared with no vaccination, vaccinating preschool-aged children averted 8%-72% of symptomatic norovirus cases in a community, whereas vaccinating older adults averted 2%-29% of symptomatic cases (varying with vaccine efficacy [25%-75%] and vaccination coverage [10%-80%]). Vaccination with a 25% vaccine efficacy was cost effective (incremental cost-effectiveness ratio ≤$50,000 per quality-adjusted life year) when vaccination cost ≤$445 and cost saving at ≤$370 when vaccinating preschool-aged children and ≤$42 and ≤$30, respectively, when vaccinating older adults. With a 50% vaccine efficacy, vaccination was cost effective when it cost ≤$1,190 and cost saving at ≤$930 when vaccinating preschool-aged children and ≤$110 and ≤$64, respectively, when vaccinating older adults. These cost thresholds (cost effective and cost saving, respectively) further increased with a 75% vaccine efficacy to ≤$1,600 and ≤$1,300 for preschool-aged children and ≤$165 and ≤$100 for older adults. CONCLUSIONS: This study outlines thresholds at which a norovirus vaccine would be cost effective and cost saving in the community when vaccinating children aged <5 years and older adults. Establishing these thresholds can help provide decision makers with targets to consider when developing and implementing a norovirus vaccine.
引用
- Bartsch SM, O'Shea KJ, Wedlock PT, et al. Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting. Am J Prev Med. 2021. PMID: 33516583. doi:10.1016/j.amepre.2020.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。